Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation最新文献

{"title":"Physical Activity, Air Pollution Exposure, and Lung Function Interactions Among Adults with COPD.","authors":"Kelly Chen, Mostafa Aglan, Alexandra Purcell, Lina Nurhussien, Petros Koutrakis, Brent A Coull, Andrew Synn, Mary B Rice","doi":"10.15326/jcopdf.2022.0385","DOIUrl":"10.15326/jcopdf.2022.0385","url":null,"abstract":"<p><strong>Rationale: </strong>Although physical activity is strongly encouraged for patients with chronic obstructive pulmonary disease (COPD), it is unknown if physical activity affects daily exposure to air pollution, or whether it attenuates or exacerbates the effects of pollution on the airways among adults with COPD.</p><p><strong>Methods: </strong>Thirty former smokers with moderate-to-severe COPD in Boston were followed for 4 non-consecutive months in different seasons. We assessed daily lung function (forced expiratory volume in 1 second [FEV₁] and forced vital capacity [FVC]), prior-day personal pollutant exposure measured by portable air quality monitors (fine particulate matter [PM_2.5] nitrogen oxide [NO₂], and ozone [O₃]), and daily step count. We constructed multi-level linear mixed-effects models with random intercepts for person and person-observation month, adjusting for demographic/seasonal covariates to test if step count was associated with daily pollution exposure, and if associations between prior-day pollution and lung function differed based on prior-day step count. Where effect modification was found, we performed stratified analyses by tertile of step count.</p><p><strong>Results: </strong>Higher daily step count was associated with higher same-day personal exposure to PM_2.5, and O₃ but not NO₂. Each interquartile range (IQR) increment in step count was associated with 0.97 µg/m³ (95%CI: 0.30, 1.64) higher exposure to PM_2.5 and 0.15 parts per billion (95% CI: -0.05, 0.35) higher exposure to O₃ in adjusted models. We observed an interaction between prior-day NO₂ and step count on FEV₁ and FVC (P_interaction<0.05) in which the negative associations between NO₂ and lung function were reduced or absent at higher levels of daily activity. For example, FEV₁ was 28.5mL (95%CI: -41.0, -15.9) lower per IQR of NO₂ in the lowest tertile of step count, but there was no association in the highest tertile of step count (-1.6mL, 95% CI: -18.4, 15.2).</p><p><strong>Conclusions: </strong>Higher physical activity was associated with modestly higher daily exposure to PM_2.5 and O₃ and may attenuate the association between NO₂ exposure and lung function.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392874/pdf/JCOPDF-10-170.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10297823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Coronavirus Disease 2019-Related Infection Prevention and Control Measures on the Occurrence of COPD Exacerbations During Inpatient Pulmonary Rehabilitation.","authors":"Kiki Waeijen-Smit, Sarah Houben-Wilke, Rein Posthuma, Fenne de Jong, Daisy J A Janssen, Nicole P H van Loon, Bita Hajian, Sami O Simons, Martijn A Spruit, Frits M E Franssen","doi":"10.15326/jcopdf.2022.0345","DOIUrl":"10.15326/jcopdf.2022.0345","url":null,"abstract":"<p><strong>Rationale: </strong>A significant reduction in hospitalizations for acute exacerbations of COPD (AECOPDs) has been reported during the coronavirus disease 2019 (COVID-19) pandemic. It remains unclear whether this reduction is the result of health care avoidance by patients, or of infection prevention and control (IPC) measures.</p><p><strong>Objectives: </strong>Our objective was to explore the impact of COVID-19-related IPC measures on the occurrence of AECOPD in a real-life inpatient pulmonary rehabilitation (PR) setting, thereby ruling out potential effects of health care avoidance.</p><p><strong>Methods: </strong>Patients with COPD admitted for 8 weeks of inpatient PR at Ciro (Horn, the Netherlands) between October 2020 and March 2021, the first winter with full COVID-19-related IPC measures,were compared to patients admitted during the same period in previous years (2017-2018, 2018-2019, and 2019-2020). Electronic medical records were retrospectively screened for the occurrence of moderate to severe AECOPDs, drop-out, and mortality.</p><p><strong>Results: </strong>A total of 501 patients with COPD (median age 66.6 [interquartile range (IQR) 60.3-71.9] years, 43.1% male, forced expiratory volume in 1 second [FEV₁] 35.9 [26.8-50.6] % predicted) were analyzed. During 2020-2021, 22 patients (31.0%) experienced ≥1 AECOPD compared to 43 patients (33.6%) in 2019-2020, 55 patients (36.9%) in 2018-2019, and 83 patients (54.2%) in 2017-2018. This represents a 25.4% reduction in 2020-2021 compared to the average of the previous 3 periods, <i>p</i>=0.077. No differences in AECOPD severity, drop-out, or mortality were observed.</p><p><strong>Conclusions: </strong>COVID-19-related IPC measures did not significantly reduce the AECOPD rate during inpatient PR in a single-center setting. The current findings suggest that avoidance of health care may be an important factor in the observed reduction of AECOPD-related hospitalizations during the pandemic and that the value of the strict COVID-19-related IPC measures for the prevention of AECOPDs warrants further research.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392876/pdf/JCOPDF-10-127.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9912981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent Steroid Exposure Before Coronavirus Disease 2019 Diagnosis and Risk of Hospitalization in Patients With Chronic Obstructive Pulmonary Disease.","authors":"Laura C Myers,&nbsp;Richard K Murray,&nbsp;Bonnie M K Donato,&nbsp;Vincent X Liu,&nbsp;Patricia Kipnis,&nbsp;Patricia Kipnis,&nbsp;Asif Shaikh,&nbsp;Jessica Franchino-Elder","doi":"10.15326/jcopdf.2022.0351","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0351","url":null,"abstract":"<p><strong>Background: </strong>It is unclear whether persistent inhaled steroid exposure in chronic obstructive pulmonary disease (COPD) patients before coronavirus disease 2019 (COVID-19) is associated with hospitalization risk.</p><p><strong>Objective: </strong>Our objective was to examine the association between persistent steroid exposure and COVID-19-related hospitalization risk in COPD patients.</p><p><strong>Study design and methods: </strong>This retrospective cohort study used electronic health records from the Kaiser Permanente Northern California health care system (February 2, 2020, to September 30, 2020) for patients aged ≥40 years with COPD and a positive polymerase chain reaction test result for COVID-19. Primary exposure was persistent oral and/or inhaled steroid exposure defined as ≥6 months of prescriptions filled in the year before the COVID-19 diagnosis. Multivariable logistic regression was performed for the primary outcome of COVID-19-related hospitalization or death/hospice referral. Steroid exposure in the month before a COVID-19 diagnosis was a covariate.</p><p><strong>Results: </strong>Of >4.3 million adults, 697 had COVID-19 and COPD, of whom 270 (38.7%) had COVID-19-related hospitalizations. Overall, 538 (77.2%) were neither exposed to steroids in the month before COVID-19 diagnosis nor persistently exposed; 53 (7.6%) were exposed in the month before but not persistently; 23 (3.3%) were exposed persistently but not in the month before; and 83 (11.9%) were exposed both persistently and in the month before. Adjusting for all confounders including steroid use in the month before, the odds ratio for hospitalization was 0.77 (95% confidence interval 0.41-1.46) for patients persistently exposed to steroids before a COVID-19 diagnosis.</p><p><strong>Interpretation: </strong>No association was observed between persistent steroid exposure and the risk of COVID-19-related hospitalization in COPD patients.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995236/pdf/JCOPDF-10-064.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9432655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Hoover's Sign with Maximal Expiratory-to-Inspiratory Pressure Ratio in Patients with COPD.","authors":"Thomas G Maloney,&nbsp;Zachary S Anderson,&nbsp;Ashley B Vincent,&nbsp;Adam L Magiera,&nbsp;Philip C Slocum","doi":"10.15326/jcopdf.2022.0341","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0341","url":null,"abstract":"<p><strong>Purpose: </strong>In chronic obstructive pulmonary disease (COPD) some patients develop paradoxical inspiratory rib motion, which is termed Hoover's sign. Our objective was to determine whether Hoover's sign is associated with a difference in the maximal expiratory pressure (MEP), the maximal inspiratory pressure (MIP), the MEP/MIP ratio, and other features on pulmonary function tests (PFTs).</p><p><strong>Methods: </strong>This observational prospective single-center cohort study enrolled patients with an established diagnosis of COPD with Global initiative for chronic Obstructive Lung Disease (GOLD) stage 3 (severe) and 4 (very severe) based on PFTs. Respiratory pressure measurements were also collected. Patients were examined for the presence or absence of Hoover's sign on physical examination by 2 internal medicine resident physicians trained in examining for Hoover's sign by a pulmonologist.</p><p><strong>Results: </strong>A total of 71 patients were examined for the presence of Hoover's sign. Hoover's sign was present in 49.3% of patients. Observer agreement (k statistic) was 0.8 for Hoover's sign. Median MEP/MIP was significantly greater in patients with Hoover's sign than those without Hoover's sign (1.88 versus 1.16, <i>p</i><0.001). Patients with Hoover's sign also had a significantly lower MIP (39.0 versus 58.0, <i>p</i><0.001) and higher residual volume (RV) to total lung capacity (TLC) ratio indicating a higher degree of air trapping (65 versus 59.5, <i>p</i><0.014).</p><p><strong>Conclusion: </strong>The presence of Hoover's sign in patients with COPD is associated with a higher MEP/MIP ratio. This suggests respiratory pressure measurements can predict diaphragm dysfunction in patients with GOLD stage 3 and 4 COPD. Patients with Hoover's sign were also found to have a lower MIP and more air trapping.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995237/pdf/JCOPDF-10-001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9079081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Care Provider Experience With Proactive E-Consults to Improve COPD Outcomes and Access to Specialty Care.","authors":"Laura J Spece,&nbsp;William G Weppner,&nbsp;Bryan J Weiner,&nbsp;Margaret Collins,&nbsp;Rosemary Adamson,&nbsp;Douglas B Berger,&nbsp;Karin M Nelson,&nbsp;Jennifer McDowell,&nbsp;Eric Epler,&nbsp;Paula G Carvalho,&nbsp;Deborah M Woo,&nbsp;Lucas M Donovan,&nbsp;Laura C Feemster,&nbsp;David H Au,&nbsp;David H Au,&nbsp;George Sayre","doi":"10.15326/jcopdf.2022.0357","DOIUrl":"10.15326/jcopdf.2022.0357","url":null,"abstract":"<p><strong>Background: </strong>Often patients with chronic obstructive pulmonary disease (COPD) receive poor quality care with limited access to pulmonologists. We tested a novel intervention, INtegrating Care After Exacerbation of COPD (InCasE), that improved patient outcomes after hospitalization for COPD. InCasE used population-based identification of patients for proactive e-consultation by pulmonologists, and tailored recommendations with pre-populated orders timed to follow-up with primary care providers (PCPs). Although adoption by PCPs was high, we do not know how PCPs experienced the intervention.</p><p><strong>Objective: </strong>Our objective was to assess PCPs' experience with proactive pulmonary e-consults after hospitalization for COPD.</p><p><strong>Methods: </strong>We conducted a convergent mixed methods study among study PCPs at 2 medical centers and 10 outpatient clinics. PCPs underwent semi-structured interviews and surveys. We performed descriptive analyses on quantitative data and inductive and deductive coding based on prespecified themes of acceptability, appropriateness, and feasibility for qualitative data.</p><p><strong>Key results: </strong>We conducted 10 interviews and 37 PCPs completed surveys. PCPs perceived InCasE to be acceptable and feasible. Facilitators included the proactive consult approach to patient identification and order entry. PCPs also noted the intervention was respectful and collegial. PCPs had concerns regarding appropriateness related to an unclear role in communicating recommendations to patients. PCPs also noted a potential decrease in autonomy if overused.</p><p><strong>Conclusion: </strong>This evaluation indicates that a proactive e-consult intervention can be deployed to collaboratively manage the health of populations with COPD in a way that is acceptable, appropriate, and feasible for primary care. Lessons learned from this study suggest the intervention may be transferable to other settings and specialties.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995235/pdf/JCOPDF-10-046.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9134728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT Trial.","authors":"J Michael Wells,&nbsp;Gerard J Criner,&nbsp;David M G Halpin,&nbsp;MeiLan K Han,&nbsp;Renu Jain,&nbsp;Peter Lange,&nbsp;David A Lipson,&nbsp;Fernando J Martinez,&nbsp;Dawn Midwinter,&nbsp;Dave Singh,&nbsp;Robert A Wise","doi":"10.15326/jcopdf.2022.0332","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0332","url":null,"abstract":"<p><strong>Background: </strong>In the InforMing the Pathway of COPD Treatment (IMPACT) trial, single-inhaler fluticasone furoate (FF) /umeclidinium (UMEC) /vilanterol (VI) significantly reduced severe exacerbation rates and all-cause mortality (ACM) risk versus UMEC/VI among patients with chronic obstructive pulmonary disease (COPD). This post hoc analysis aimed to define the risk of ACM during and following a moderate/severe exacerbation, and further determine the benefit-risk profile of FF/UMEC/VI versus FF/VI and UMEC/VI using a cardiopulmonary composite adverse event (AE) endpoint.</p><p><strong>Methods: </strong>The 52-week, double-blind IMPACT trial randomized patients with symptomatic COPD and ≥1 exacerbation in the prior year 2:2:1 to once-daily FF/UMEC/VI 100/62.5/25mcg, FF/VI 100/25mcg, or UMEC/VI 62.5/25mcg. Post hoc endpoints included the risk of ACM during, 1-90 and 91-365 days post moderate or severe exacerbation and time-to-first cardiopulmonary composite event.</p><p><strong>Results: </strong>Of the 10,355 patients included, 5034 (49%) experienced moderate/severe exacerbations. Risk of ACM was significantly increased during a severe exacerbation event compared with baseline (hazard ratio [HR]: 41.22 [95% confidence interval (CI) 26.49-64.15]; <i>p</i><0.001) but not significantly different at 1-90 days post-severe exacerbation (HR: 2.13 [95% CI: 0.86-5.29]; <i>p</i>=0.102). Moderate exacerbations did not significantly increase the risk of ACM during or after an exacerbation. Cardiopulmonary composite events occurred in 647 (16%), 636 (15%), and 356 (17%) patients receiving FF/UMEC/VI, FF/VI, and UMEC/VI, respectively; FF/UMEC/VI significantly reduced cardiopulmonary composite event risk versus UMEC/VI by 16.5% (95% CI: 5.0-26.7; <i>p</i>=0.006).</p><p><strong>Conclusion: </strong>Results confirm a substantial mortality risk during severe exacerbations, and an underlying CV risk. FF/UMEC/VI significantly reduced the risk of a composite cardiopulmonary AE versus UMEC/VI.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995234/pdf/JCOPDF-10-033.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9079941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical Activity and Symptom Burden in COPD: The Canadian Obstructive Lung Disease Study.","authors":"Loes Oostrik,&nbsp;Jean Bourbeau,&nbsp;Dany Doiron,&nbsp;Bryan Ross,&nbsp;Pei Zhi-Li,&nbsp;Shawn D Aaron,&nbsp;Kenneth R Chapman,&nbsp;Paul Hernandez,&nbsp;Francois Maltais,&nbsp;Darcy D Marciniuk,&nbsp;Denis O'Donnell,&nbsp;Wan C Tan,&nbsp;Don D Sin,&nbsp;Brandie Walker,&nbsp;Tania Janaudis-Ferreira","doi":"10.15326/jcopdf.2022.0349","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0349","url":null,"abstract":"<p><strong>Background: </strong>The relationship between symptom burden and physical activity (PA) in chronic obstructive pulmonary disease (COPD) remains poorly understood with limited data on undiagnosed individuals and those with mild to moderate disease.</p><p><strong>Objective: </strong>The primary objective was to evaluate the relationship between symptom burden and moderate-to-vigorous intensity PA (MVPA) in individuals from a random population-based sampling mirroring the population at large.</p><p><strong>Methods: </strong>Baseline participants of the Canadian Cohort Obstructive Lung Disease (n=1558) were selected for this cross-sectional sub-study. Participants with mild COPD (n=406) and moderate COPD (n=331), healthy individuals (n=347), and those at risk of developing COPD (n=474) were included. The Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire was used to estimate MVPA in terms of energy expenditure. High symptom burden was classified using the COPD Assessment Test ([CAT] ≥10).</p><p><strong>Results: </strong>Significant associations were demonstrated between high symptom burden and lower MVPA levels in the overall COPD sample (β=-717.09; 95% confidence interval [CI]=-1079.78, -354.40; <i>p</i><0.001) and in the moderate COPD subgroup (β=-694.1; 95% CI=-1206.54, -181.66; <i>p</i>=0.006). A total of 72% of the participants with COPD were previously undiagnosed. The undiagnosed participants had significantly higher MVPA than those with physician diagnosed COPD (β=-592.41 95% CI=-953.11, -231.71; <i>p</i>=0.001).</p><p><strong>Conclusion: </strong>MVPA was found to be inversely related to symptom burden in a large general population sample that included newly diagnosed individuals, most with mild to moderate COPD. Assessment of symptom burden may help identify patients with lower MVPA, especially for moderate COPD and for relatively inactive individuals with mild COPD.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995232/pdf/JCOPDF-10-089.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9432671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urine and Plasma Markers of Platelet Activation and Respiratory Symptoms in COPD.","authors":"Ashraf Fawzy,&nbsp;Nirupama Putcha,&nbsp;Sarath Raju,&nbsp;Han Woo,&nbsp;Cheng Ting Lin,&nbsp;Robert H Brown,&nbsp;Marlene S Williams,&nbsp;Nauder Faraday,&nbsp;Meredith C McCormack,&nbsp;Nadia Hansel","doi":"10.15326/jcopdf.2022.0326","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0326","url":null,"abstract":"<p><strong>Introduction: </strong>Antiplatelet therapy has been associated with fewer exacerbations and reduced respiratory symptoms in chronic obstructive pulmonary disease (COPD). Whether platelet activation is associated with respiratory symptoms in COPD is unknown.</p><p><strong>Methods: </strong>Former smokers with spirometry-confirmed COPD had urine 11-dehydro-thromboxane B2 (11dTxB2), plasma soluble CD40L (sCD40L), and soluble P-selectin (sP-selectin) repeatedly measured during a 6- to 9-month study period. Multivariate mixed-effects models adjusted for demographics, clinical characteristics, and medication use evaluated the association of each biomarker with respiratory symptoms, health status, and quality of life.</p><p><strong>Results: </strong>Among 169 participants (average age 66.5±8.2 years, 51.5% female, 47.5±31 pack years, forced expiratory volume in 1 second percent predicted 53.8±17.1), a 100% increase in 11dTxB2 was associated with worse respiratory symptoms reflected by higher scores on the COPD Assessment Test (β 0.77, 95% confidence interval [CI]: 0.11-1.4) and Ease of Cough and Sputum Clearance Questionnaire β 0.77, 95%CI: 0.38-1.2, worse health status (Clinical COPD Questionnaire β 0.13, 95%CI: 0.03-0.23) and worse quality of life (St George's Respiratory Questionnaire β 1.9, 95%CI: 0.39-3.4). No statistically significant associations were observed for sCD40L or sP-selectin. There was no consistent statistically significant effect modification of the relationship between urine 11dTxB2 and respiratory outcomes by history of cardiovascular disease, subclinical coronary artery disease, antiplatelet therapy, or COPD severity.</p><p><strong>Conclusions: </strong>In stable moderate-severe COPD, elevated urinary11dTxB2, a metabolite of the platelet activation product thromboxane A2, was associated with worse respiratory symptoms, health status, and quality of life.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995228/pdf/JCOPDF-10-022.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9077953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Influence of Provider Connectedness on Continuity of Care and Hospital Readmissions in Patients With COPD: A Claims Data Based Social Network Study.","authors":"Johanna Forstner,&nbsp;Jan Koetsenruijjter,&nbsp;Christine Arnold,&nbsp;Gunter Laux,&nbsp;Michel Wensing","doi":"10.15326/jcopdf.2022.0359","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0359","url":null,"abstract":"<p><strong>Background: </strong>Hospital readmission rates are very high in patients with chronic obstructive pulmonary disease (COPD). Continuity of care (CoC) with general practitioners (GPs) and ambulatory specialists can impact readmission rates. This study aimed to identify shared patient networks of ambulatory care physicians and to examine the effect of provider connectedness on CoC and hospital readmissions.</p><p><strong>Methods: </strong>A retrospective observational study was conducted in claims data from the years 2016 to 2018 in patients with COPD (aged 40 years or older; hospital stay in 2017). Linkages between GPs, pneumologists, and cardiologists were determined on the basis of shared patients. Multilevel regression models were used to analyze the impact of provider connectedness, operationalized by several social network characteristics, on continuity of care (sequential continuity [SECON] index) and hospital readmission rates.</p><p><strong>Results: </strong>A total of 7294 patients linked to 3673 GPs were available for analysis. Closeness centrality (β=- 0.029) and the external-internal (EI)-index (β =0.037) impacted on the SECON index. The EI-index (odds ratio [OR]=1.25) and degree centrality (OR=1.257) impacted 30-day readmission. Network density (OR=0.811) and the SECON index (OR=1.121) affected the likelihood of a 90-day readmission. None of the predictors had a significant impact on 180-day and 365-day readmissions.</p><p><strong>Conclusions: </strong>Ambulatory care providers' connectedness showed some effects on hospital readmissions and CoC in patients with COPD up to 90 days after hospital discharge, but the additional predictive power is limited.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995233/pdf/JCOPDF-10-077.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9079938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ambient Air Pollution Exposure and Sleep Quality in COPD.","authors":"Mudiaga O Sowho, Abigail L Koch, Nirupama Putcha, Han Woo, Amanda Gassett, Laura M Paulin, Kirsten Koehler, R Graham Barr, Alejandro P Comellas, Christopher B Cooper, Igor Barjaktarevic, Michelle R Zeidler, Martha E Billings, Russell P Bowler, MeiLan K Han, Victor Kim, Robert Paine Iii, Trisha M Parekh, Jerry A Krishnan, Stephen P Peters, Prescott G Woodruff, Aaron M Baugh, Joel D Kaufman, David Couper, Nadia N Hansel","doi":"10.15326/jcopdf.2022.0350","DOIUrl":"10.15326/jcopdf.2022.0350","url":null,"abstract":"<p><strong>Rationale: </strong>Ambient air pollution exposure is associated with respiratory morbidity among individuals with chronic obstructive pulmonary disease (COPD), particularly among those with concomitant obesity. Although people with COPD report high incidence of poor sleep quality, no studies have evaluated the association between air pollution exposure, obesity, and sleep disturbances in COPD.</p><p><strong>Methods: </strong>We analyzed data collected from current and former smokers with COPD enrolled in the Subpopulations and Intermediate Outcome Measures in COPD -Air Pollution ancillary study (SPIROMICS AIR). Socio-demographics and anthropometric measurements were collected, and 1-year mean historical ambient particulate matter (PM_2.5) and ozone concentrations at participants' residences were estimated by cohort-specific spatiotemporal modeling. Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI), and regression models were constructed to determine the association of 1-year PM_2.5 (1Yr-PM_2.5) and 1-year ozone (1Yr-ozone) with the PSQI score, and whether obesity modified the association.</p><p><strong>Results: </strong>In 1308 participants (age: 65.8±7.8 years, 42% women), results of regression analyses suggest that each 10µg/m³ increase in 1Yr-PM_2.5 was associated with a 2.1-point increase in PSQI (<i>P</i>=0.03). Obesity modified the association between 1Yr-PM_2.5 and PSQI (<i>P</i>=0.03). In obese and overweight participants, a 10µg/m³ increase in 1Yr-PM_2.5 was associated with a higher PSQI (4.0 points, <i>P</i><0.01, and 3.4 points, <i>P</i><0.01, respectively); but no association in lean-normal weight participants (<i>P</i>=0.51). There was no association between 1 Yr-ozone and PSQI.</p><p><strong>Conclusions: </strong>Overweight and obese individuals with COPD appear to be susceptible to the effects of ambient PM_2.5 on sleep quality. In COPD, weight and ambient PM_2.5 may be modifiable risk factors to improve sleep quality.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995229/pdf/JCOPDF-10-102.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10305215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}